When you've figured out the difference, people will walk through fire for you, a mentor once told her.
Technology executives discussed how pharma companies can leverage social media to better engage with patients online.
PhRMA hires Ubl as CEO; two drugs report superior results in kidney-cancer trials compared to the standard of care; Novo Nordisk's shares rise on Tresiba approval
Craig Rothenberg joined Turing as its first comms chief less than two months ago.
Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.
Allergan executives attributed strong sales of branded products to recent investments in direct-to-consumer advertising.
AstraZeneca signs two immuno-oncology collaboration deals; UK cost watchdog goes after Pfizer over epilepsy medication price tag; Boston Globe reports drugmakers are funneling more money through CME programs
Eylea's robust second quarter of sales can be attributed in part to its ability to erase market share of competitors.
The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.
Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010
Test your knowledge in this week's edition of the MM&M Weekly News Quiz.
Lawsuit alleges CVS overbilled insurance companies for generic drugs; a Merck vaccine is shown to be effective in treating Ebola; the FDA approves Bayer's rosacea treatment
Turing Pharmaceuticals hired Craig Rothenberg, who spent 20 years with Johnson & Johnson, to lead the recently founded drugmaker's communications operations.
Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.
Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment
The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.
Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.
Bristol-Myers Squibb reported a dip in US sales for the second quarter of 2015 but noted higher uptake for its immunoncology drug, Opdivo.
Oncologists criticize cancer drug prices; Mylan exercises option to fend off Teva takeover; Valeant buys IBS diagnostic in latest acquisition
A next-generation cardiovascular drug is expected to be approved this week, but concerns abound about who will take it—and how much it will cost.
The new campaign seeks to connect with millennial women.
Robert Ingram sounds off on drug transparency laws in WSJ op-ed; patients with certain forms of leukemia went into complete remission after taking Amgen's cancer drug; Eli Lilly's future in Alzheimer's disease pinned to new data surfacing this week
The backlash to expensive specialty medications has forced the drug industry to partner up to prove the benefits of their medicines in the real world, according to a PwC analysis.
The restructuring is expected to simplify the drugmaker's organization.
Harvoni is now prescribed more than Sovaldi; healthcare group says new hepatitis-C drugs are cost-effective; Roche antibody shrank tumors in certain bladder-cancer patients
21st Century Cures legislation passes the House; Novartis's heart-failure drug may launch with "beyond the pill" services; Purdue and GSK are working on using Apple's ResearchKit; the FDA issues warning letter on co-pay card
An FDA advisory panel will discuss the fate of Lilly's investigational lung-cancer antibody, necitumumab, which improved overall survival incrementally but also had one late-stage trial halted due to an "imbalanced number of deaths" attributed to blood clots.
An analysis by a state insurance trade group forecast that paying for new HCV treatments could cost taxpayers billions of dollars.
The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.
Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company